Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
50567-35-6
Molecular formula
C13H17N3O4S
Molecular weight
311.36 g/mol
Drug class
Pyrazolone analgesic and antipyreticnon-opioid pain reliever with spasmolytic activity
Mechanism of action
The exact mechanism is not fully established. Metamizole and its metabolites produce analgesic, antipyretic and spasmolytic effects; proposed actions include central and peripheral modulation of prostaglandin pathways and other pain-signalling mechanisms.
Indications / reported uses
Acute severe pain following trauma or surgery
Painful colic and other severe pain when alternative measures are inadequate or contraindicated
High fever unresponsive to other measures, only in jurisdictions and formulations where authorised; use is restricted in some countries because of agranulocytosis risk
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Metamizole PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Metamizole Permitted Daily Exposure (PDE) report (the Metamizole PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Metamizole Occupational Exposure Limit (OEL) report (the Metamizole OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.